Annual & Sustainability Report 2021

Driving sustainable care together

Chiesi in 2021

The need for an increasingly sustainable world to benefit the health of the planet and civilization, is clearer than ever. At Chiesi, we are acutely aware of this need. The starting point for all our actions centres around one simple question: how can we provide outstanding therapeutic solutions and improve people’s quality of life worldwide while driving a sustainable and responsible business?

“The health of our planet and its inhabitants deserves our best efforts, which is why Chiesi will continue promoting a regenerative business model capable of creating positive results today and for future generations.”

Alberto ChiesiPresident of Chiesi Group

For almost 90 years, Chiesi has been synonymous with delivering transformative solutions that change lives. From our founder Giacomo Chiesi, whose dreams of embarking on cutting-edge research led him to start the company in 1935, all the way through to the creation of Chiesi Global Rare Diseases in 2020 – with many more notable milestones in between – our company has always been driven by the desire to leave a positive footprint for the future.

Our aim 

is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.

We wish

to maintain a team characterised by innovative pharmaceutical self-confidence and a collaborative spirit.

Our goal

is to combine commitment to results with integrity, operating in a socially and environmentally responsible manner.

Our mission

Our mission is to provide outstanding therapeutic solutions and improve people’s quality of life worldwide.

Our vision

By 2025 we aspire to be a reference point for patients living with chronic respiratory disorders, neonatal pathologies, rare diseases and other difficult-to treat health conditions. We commit to offering patients, and their caregivers, innovative solutions to help meet their needs, by exploring new frontiers in treatment and care and embracing state-of-the-art technologies. As a family owned company, we want to continue growing sustainably by focusing on key markets such as the U.S. and Europe, while expanding access to care in emerging countries like China. We aim to maintain a profitability level adequate to support our investments in innovation and development and our international expansion efforts.

“There is no doubt that the impact of the pandemic will remain with us for many years to come. While remembering those lives lost and disrupted, we have all been forced to re-evaluate the status quo and ask ourselves how to move forward.”

Ugo Di FrancescoCEO of Chiesi Group

Sustainability at Chiesi

As a Benefit Corporation, we want to act as a force for good, doing business in a way that generates a positive impact on society and nature and become an inspiration to our stakeholders in the biopharmaceutical industry. Achieving this demands teamwork and care for the well-being of the people we work with. By leveraging diversity and creativity, we seek to promote a working environment that welcomes everyone’s contribution and rewards personal accountability. The We Act sustainability manifesto guides our corporate efforts in the area of sustainability and is the core of all our actions.

Spotlight

Sustainability Manifesto

We live in a time of great changes. The planet is exploited beyond its limits and its equilibriums are in continuous transformation. We are changing ourselves in the way we live and think about our society. The most fragile and vulnerable are paying the price: those who are often left behind in this rush forward.

At Chiesi we have always believed that it is necessary to take care of our planet and the people who inhabit it, rediscovering the value of mutual solidarity, as we are aware that every individual, as well as every living organism, is unique and irreplaceable.

This is why we want to make the assurance of high-quality medical research available for the most fragile individuals so that we can closely listen to and understand them as people rather than as patients.

We want to act as a force for good, promoting a conscious and different way of doing business which strives to achieve a positive impact on society and nature by handling resources in a circular way and creating a new harmony and sustainability. The well-being of all depends on this balance. For us, this is the only true form of progress.

Our team of professionals is highly motivated and open-minded as our culture guides us, valuing the diversity of each individual.

Spotlight

Sustainable Development Goals

Chiesi is also committed to playing a part in advancing the United Nations Sustainable Development Goals (UN SDGs). While we firmly believe in the importance of all 17 goals for achieving a fairer and more prosperous world for all, there are nine goals in particular which we think are best positioned to support through our work:

#3 Good health and well-being, #5 Gender equality, #8 Decent work and economic growth, #9 Industry, innovation and infrastructure, #10 Reduced inequalities, #11 Sustainable cities and communities, #12 Responsible consumption and production, #13 Climate action, #17 Partnerships for the goals.

Since 2020, we use the SDG Action Manager Tool to assess, compare and improve our performance to deliver tangible progress on the SDGs. 2021 marked an improvement in our overall performance against the SDGs: while acknowledging that Chiesi’s activities pose no potential risks to the achievement of any of the SDGs, the analysis showed that Chiesi positively contributes to many of them, outperforming the average country and sector scores in many cases. We achieved a very high score on SDG #3: Good Health and Well-Being (the only SDG directly linked to Chiesi’s business model), which highlights how our business contributes to sustainable development by enabling healthy lives and promoting well-being for all, at all ages.

Spotlight

Path towards B-Corp recertification

As the largest global pharmaceutical company to be certified as a Benefit Corporation, Chiesi constantly monitors and improves the societal and environmental performances throughout its operations. Alongside our company mission of developing and commercialising medicines to improve patients’ quality of life, we have integrated four common benefit goals into our bylaws. These focus on creating a positive impact on society and the environment, thus embedding the concept of creating shared value into how we put action into words. Under this overarching framework, the Chiesi community constantly focuses on improving areas of synergy, helping to drive even greater impact for all stakeholders and partners. This is facilitated by establishing yearly improvement plans directly related to impact areas. Since becoming a Benefit Corporation under the Italian and US law in 2018 and being certified as B Corp in 2019, Chiesi self-assesses its sustainability performance on a yearly basis, as part of our own corporate commitment to constantly measure our progress in key areas and implement further improvement actions. In order to maintain B Corp certification, companies must update their impact assessment every three years, to verify their status and update their score. In 2022 we are required to seek recertification as a B Corp for the first time since joining. After submitting all relevant material to B Lab in 2021, Chiesi is currently undergoing the audit phase of this process

Four Common Benefit Purposes

Improving people’s health, wellbeing and quality of life.

Promoting a conscious and sustainable way of doing business, by fostering a collaborative dialogue among stakeholders.

Contributing to the development of the local communities in which the company operates.

Continuously innovating the sustainability of all company processes and practices in order to minimise negative impacts and to amplify positive impacts on people, the biosphere and the community, in pursuit of an economy with net-zero GHG emissions, in line with European objectives on climate neutrality and national objectives on ecological transition.

Revenues

2,420
Total Group Revenues

Revenues by focus area

Air

1,731

Rare

279

Care

409

EBITDA (% on revenues)

2021 | 772.8m EUR

31.9%

2020 | 744.2m EUR

33.4%

2019 | 626.1m EUR

31.4%

2019 | 512.7m EUR

29%

Our workforce

6,146
Internal Employees
54
Women
46
Men
406
External Collaborators
994
Employees working in R&D
66
Women in R&D

Governance, Mission & Engagement

To advance sustainable transformation together, Chiesi has established several governance frameworks to ensure we operate in a responsible, sustainable and transparent way towards patients and their caregivers, our colleagues, the planet and our communities.

The big picture

Companies are being rightly held accountable and scrutinised for the impact they have on the world. As the World Economic Forum points out, “it is no longer acceptable for companies to make empty promises and leave behind the action.” Employees, customers, consumers and society at large expect corporations to create value for society beyond simply generating profit. This change is also reflected in regulatory frameworks, such as the EU Corporate Sustainability Reporting Directive (CSRD) which is expected to come into effect in 2022 and make reporting on Environmental, Social, and Governance (ESG) issues a mandatory requirement for companies all across Europe.

The Chiesi view

Chiesi uses the B Impact Assessment third party standard, the assessment tool which forms the basis of B Corp certification to report on the impact we generate. We also have an Impact Committee, which is responsible for defining sustainability objectives in line with our purpose of common benefit expressed in our corporate by-laws. The Group is engaged at an international level to follow the continuous evolution of the ESG frameworks and promote a stronger global harmonisation. We have a specific strategy that guides our actions in local communities, with a dedicated governance body at Headquarter level, the Committee for Social and  Community Development Activities.

Spotlight

B Corp

In 2018, Chiesi adopted the new legal status of Benefit Corporation, for the creation of shared value and in June 2019, Chiesi was awarded B Corp certification by B Lab. In March 2021, Chiesi joined the B Corp Climate Collective (BCCC), committing to the United Nations Framework Convention on Climate Change (UNFCCC) “Race to Zero”. In April 2021, Chiesi France was announced as the healthcare sector’s first “Société à mission” (SAM).

2021 also saw us begin the process of re-certifying our B Corp status, by compiling details of our progress to date and plans for the future – with the audit phase of the process set to conclude in July 2022.

Spotlight

We ACT

“We Act”, also known as “We Actively Care for Tomorrow”, is the expression of Chiesi’s sustainability commitment. It is a manifesto which expresses our brand truth, and which aims to set the direction and tone for everything we do, building on Chiesi’s desire to take care of society and the environment through awareness-raising projects and by actively involving all of our people.

The health of our planet and its inhabitants deserves our best efforts

Measuring our impact

Chiesi’s Evidence Generation Plan is focused on demonstrating how our products are having an impact on people’s lives, in ways that cannot be measured by clinical endpoints but rather by interviewing patients and looking at their behaviors, feelings and needs. Our clinical department is also working to improve patient experiences during clinical trials, through decentralisation and the implementation of more patient-friendly trial designs.

Data privacy & security

As part of our 2021 Materiality Analysis, we also identified one new addition to the priority topics list: Privacy and Data Security. This reflects our increased focus on keeping sensitive healthcare and other personal data safe and secure, in order to build trust with our stakeholders and prevent negative impacts for our business. While a strong focus in this context is placed on patient data, Chiesi follows stringent guidelines for the processing and use of all types of data and in all of the company’s operations, as required by the relevant Data Protection Authorities. To this end, we are fully compliant with the rules laid out in the European General Data Protection Regulation (GDPR, EU Regulation No 679/2016).

Our impact across the globe

Benefit Corporation

Sweden

Benefit Corporation

During 2021 Chiesi Nordic started looking into Swedish corporation legislation. Current legislation assumes that the objective of a company is to provide profit to its owners, or that the business has profit limitations. There is no legislation encouraging companies to simultaneously make profit and have a higher purpose. Therefore, we prepared a presentation on benefit corporation and presented it to a handful of decision makers and parliament members to increase awareness. We have also inspired a motion on the topic in the parliament.

Chiesi helps

Germany

Chiesi helps

The fact that Chiesi is a certified B-Corp has an overarching effect on how the company is led and governed, both at headquarter and affiliate level, and involves taking responsibility to support the communities the company operates in. Within this context, Chiesi Germany regularly helps people in situations of emergency (disaster relief). In 2021 donations were made with a focus on patient organisations, emergency help or a part of “Chiesi doubles your donation” (where the company doubles donations by employees to non-profit organisations). One of the priorities last year was the support of communities and families that were struck by the flood catastrophe along the Ahr river in July 2021. German Chiesi colleagues also volunteered in the emergency help and logistics on site.

Société à mission

France

Société à mission

In April 2021 Chiesi SAS was the first pharmaceutical company to become a société à mission (mission-driven company). In this regard, the French affiliate set its purpose to “take care of patients and the planet today for tomorrow” defining three commitments as part of this aim which have been integrated into its by-laws. These include innovating with stakeholders, acting for diversity and inclusion and contributing to environmental protection. A committee of 12 external and internal stakeholders was appointed to ensure the execution of this goal. Together, this group will develop roadmaps based on these commitments, with precise indicators to enable monitoring the progress of the actions undertaken. In April 2022 the first mission report will be published to present progress to-date and to highlight areas for future improvement.

Swedish Pharma Industry Association

Sweden

Swedish Pharma Industry Association

In 2021 the MD of Chiesi Nordic was elected to the Board of the Swedish Pharma Industry Association. Thereby Chiesi got access to a platform to enhance sustainability in the pharma industry. In addition to participating in several panels, podcasts and presentations, being on the Board gave us the opportunity to initiate and support the Secretariat as well as other progressive members in developing a sustainability manifesto, to be launched for the entire industry during 2022. Our sustainability work has also been recognised in the other Nordic countries.

Patients

Chiesi is committed to serving patients with outstanding therapeutic solutions that improve their quality of life, so that they can live as part of a community, undefined by their disease, while also delivering shared value for wider society and the planet.

The Chiesi view

Chiesi’s mission is to provide outstanding therapeutic solutions and improve people’s quality of life worldwide. This is the foundation for our sustainable business approach, which seeks to generate a wider impact for society, the environment and other stakeholders.

Our ambition

We consider ourselves as a reference point for people living with chronic respiratory disorders, neonatal pathologies, rare diseases and other difficult-to-treat health conditions. We are committed to offering innovative solutions by exploring new frontiers in treatment and care and embracing state-of-the-art technologies. Patients do not exist in isolation. They are active and empowered members of our societies, forming part of the same communities and living in the same environment as all of us. This is why, at Chiesi, we believe true patient care must extend beyond manufacturing drugs – into the societal impact of our decisions.

EFPIA

As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), Chiesi has also adopted mechanisms to enable sharing of clinical trial information and results with trial participants and the general public, consistent with applicable laws.

Patient Engagement

We give our patients and their loved ones the support needed to live more active and fulfilling lives throughout the entire health journey. To be able to do that, we listen to their voice every step of the way; we involve patients in the definition of meaningful outcomes and the design of endpoints; we constantly engage with associations representing those who live with severe diseases to gather feedback on our solutions and we facilitate participation in clinical studies and questionnaires to collect and assess patient-reported outcomes of clinical trials.

Partnerships

In the field of advocacy, we are working in partnership with patients to create awareness and improve patient care even further. We particularly concentrate our efforts in the Respiratory and Rare therapeutic areas.

Air

Diseases covered:

Asthma and COPD, Neonatal, Cystic Fibrosis

Encompasses products and services that enable the treatment of respiratory pathologies among patients of all ages, from newborns to the elderly.

Chiesi is committed to supporting people with respiratory diseases, including asthma and Chronic Obstructive Pulmonary Disease (COPD), to achieve fulfilled lives. In April, we received European marketing authorization for our triple combination therapy inhalation powder, for the treatment of moderate to severe COPD.

In the area of neonatalogy, our R&D programmes include novel and less-invasive methods for the targeted delivery of Curosurf, a life-saving surfactant used to treat neonatal RDS.

In March, Chiesi USA launched the FDA-approved Bronchitol® (mannitol) inhalation powder, to improve pulmonary function in adult cystic fibrosis (CF) patients.

Rare

Diseases covered:

Inborn errors of metabolism, rare hematologic and immunologic diseases, ophthalmology disorders

Focuses on the treatment of patients living with rare or ultra-rare diseases.

Chiesi Global Rare Diseases (GRD), which counts 275 Chiesi employees and is active in 20 countries, is has been driven to help individuals impacted by rare diseases. We received approval from the FDA, Health Canada and Brazil’s National Health Surveillance Agency for the use of FERRIPROX® (deferiprone) for the treatment of transfusional iron overload due to sickle cell disease (SCD) or other anemias in adult and pediatric patients.

Care

Diseases covered:

Solid organ transplant, cardiovascular diseases, Consumer Healthcare/ Over the Counter

Combines products and services that support special care provided by medical professionals, as well as consumer-facing self-care.

Our work in special care includes support for patients undergoing solid organ transplant (SOT) and cardiovascular diseases (CVDs), which are the number one cause of death worldwide.

Our Consumer Healthcare portfolio covers several branded products that provide people with a range of healthcare and self-care solutions to enhance their health and wellbeing. It includes local OTC products available in Italy, Spain, Germany, Brazil and Greece, which include cough and cold, probiotics, intestinal diseases, weight loss, cream, patches for pain and others, and the NHCO Nutrition product offering.

Innovating for the future

Our research and development (R&D) function plays a key role in generating sustainable value – for our business and beyond. Approximately 81% of Chiesi’s turnover is generated from products developed as a result of internal research.

R&D Spending by Therapeutic Area in 2021

19.8
of our revenues were dedicated to R&D
479
Total expenses in R&D
70.7
Respiratory
13.1
Rare Disease
8.4
Neonatology
7.8
Special Care

Measuring our impact

Chiesi’s Evidence Generation Plan is focused on demonstrating how our products are having an impact on people’s lives, in ways that cannot be measured by clinical endpoints but rather by interviewing patients and looking at their behaviors, feelings and needs. Our clinical department is also working to improve patient experiences during clinical trials, through decentralisation and the implementation of more patient-friendly trial designs.

Partnering to provide the best quality of care to people with allergy and airways diseases

A word from our stakeholders

Susana Palkonen

Director, Breathe Coalition

Over the years, Chiesi has been instrumental in supporting us to deliver on its long-term vision of a world where all people with allergy and airways diseases have access to the best quality of care and are involved in all decisions on their health. Chiesi’s support has been increasing over time to focus not only on prevention, but also on care, and we are very grateful for this continuous partnership.”

Our impact across the globe

Lifully App

Italy

Lifully App

The LIFULLY app is a national initiative which aims to increase the user’s importance of knowing about breathing better and promoting a healthy lifestyle amongst the general population. Breathing exercises help people listen to and train their breathing step-by-step to improve their physical and mental well-being. So far there have been more than 35,000 downloads of the app and it has secured a score of 4.7 out of 5 from users.

SASHP research programme

United States

SASHP research programme

Chiesi partnered with the Pharmacy Leadership Scholars (ASHP) Foundation to launch a programme to progress diversity, equity and inclusion in the healthcare industry. The programme sponsorship aligns with Chiesi’s corporate social responsibility aim, Chiesi in the Community, to support local nonprofit and patient organisations in the company’s therapeutic areas. Those selected participated in an Impact Collaborative, a distance-engagement component facilitated by a group coach to support project progress and enhance critical insights, leadership and research skills.

Lungs under control

Czech Republic

Lungs under control

Chiesi Czech, under their commitment to the care and improve the quality of life for people suffering from respiratory disease, developed a webpage called “Lungs under control”. The online resource provides patients and physicians with educational material on respiratory health including brochures, videos and webinars for patients and physicians.

Pequeño Nunu Foundation collaboration

Mexico

Pequeño Nunu Foundation collaboration

On World Premature Day (November 17th), an alliance was created with the Pequeño Nunu Foundation, a group of parents, volunteers and professionals who provide health and family support and advice to families of premature babies. Employees and followers on  social channels were invited to wear purple and upload a photo on LinkedIn or Facebook using #PrematureDay. For each photo shared, Chiesi donate $5 MXN to the Foundation.

Environment

As a B Corp, Chiesi is constantly working to understand its impact on the environment and believes that the health of the planet and human health are inextricably linked. Taking a long-business approach to our business means that health does not just encompass patients but also employees, communities and the built environment, too.

The Chiesi view

At Chiesi we believe that the health of the planet and human health are inextricably linked and that we all have a role to play in protecting the environment. With this in mind, all business decisions are made in a way that we assess their environmental impacts and, where possible, we aim to reduce them further. We take a long-term business approach, bearing in mind both current and future generations. In this way the concept of health at Chiesi encompasses not only that of its employees, but also that of the community, the built environment and the planet.

Our ambition

Chiesi is committed to reducing its impact on the environment to benefit the health of current and future generations. As a B Corp, our company constantly strives to understand its impact and how to further our achievements to increase the positive value we create, and we are taking radical steps to do this in a comprehensive way.

Key targets and progress

GHG Emissions Inventory

Direct (Scope 1) GHG emissions

43,709
tonnes CO2e

Biogenic CO2 emissions

1,944
tonnes CO2e

Energy indirect (Scope 2) GHG emissions (location based)

12,376
tonnes CO2e

Energy indirect (Scope 2) GHG emissions (market based)

1,818
tonnes CO2e

Other indirect (Scope 3) GHG emissions

802,048
tonnes CO2e

Challenges

The road towards carbon neutrality is a tough one and is full of challenges. Chiesi aims to be bold in its goals for this area though we are also aware it is a difficult journey with obstacles and one where we are likely to experience setbacks. Given this, we will need to readjust our route based on unexpected outcomes but will always communicate this journey in a transparent way. We are mindful that achieving our aims will require a strong effort from all those involved and that it is a fine balance between reducing the impact on the planet in the short-term versus investing to build improved solutions for the future.

Our pathway to neutrality

Our carbon neutrality goals include becoming carbon neutral by 2030 on direct greenhouse gas (GHG) emissions (scope 1) and indirect GHG emissions from purchased electricity and heat (scope 2), and on all the other indirect GHG emissions (scope 3) by 2035. In order to show complete transparency in this area and to strengthen our credibility, in 2021 our carbon neutrality  targets have been validated by the Science Based Targets initiative (SBTi), reassuring our stakeholders of our commitment to reduce our GHG emissions consistently with the level of decarbonisation required by the Paris Agreements.

In 2021, Chiesi joined the Carbon Disclosure Project, a not-for profit charity that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts.

Better Building

Better Building is a global programme with the aim of improving the well-being of people working in our buildings as well as the sustainability performance of our sites, by reducing the environmental impact on natural systems and local communities, from the processes of new constructions to the operations of existing structures. In 2021, we had 3 sites undergoing certification path according to LEED standards, 4 projects under alignment with Chiesi internal standards and 6 sites supported in applying Green Operating Guidelines.

E-Mobility

Mobility is another significant area in the journey towards the reduction of our GHG emissions. We continue to put our efforts into reducing the environmental impact of our transportation structure. This includes reducing the emissions of our own corporate car fleet, as well as encouraging our employees to opt for more environmentally friendly transportation means, such as cycling or public transport.

In 2021, 43 charging stations (2 points) and 12 wall boxes were installed at our Italian sites and 34 additional hybrid cars were inserted into the car fleet. The 2022 activity foresees the installation of 43 charging stations (reaching a total of 86 charging columns across the Italian sites), 26 wall boxes and the substitution of about 50 fossil fuel cars with hybrid / electric models.

Spotlight

Carbon Minimal Inhaler

One of the main projects that Chiesi is working on, as a means to reduce emissions derived from the therapies we provide, is the Carbon Minimal Inhaler project. This project is of the utmost importance for Chiesi, because one of our greatest contributors to GHG emissions comes from the use of the propellant contained in some of our devices for inhalation of antiasthmatic drugs. The challenge this project aims to overcome is the high climate-altering effect caused by the propellant gas present in one type of inhaler: the so-called pressurised metered-dose inhalers (pMDIs) or spray inhalers, which serve to release the drugs effectively. The goal Chiesi has set is to replace the current propellant with a new one, called HFA152a, which has a much lower Global Warming Potential (GWP), in order to reduce the impact and make inhalers more sustainable. In 2019, Chiesi was the first company to announce such a solution to reduce the carbon footprint of inhalers by up to 90%. The Carbon Minimal Inhaler project requires a true cross-functional effort, encompassing extensive R&D work, to ensure that the efficacy, safety and usability of our products remains well above standards, together with a comprehensive manufacturing plan including the building of a first-in-class facility in Blois, France. In 2021, we continued to progress at pace, alongside our plan to deliver the first Carbon Minimal Inhaler by 2025. We have entered into the first clinical trials, aimed at proving the efficacy and safety of these products, and at the same time work progressed at our manufacturing facility that will support the next phases of development.
A word from our stakeholders

Simon Gardner

Business Development Director, Koura

Koura is a global leader in the development, manufacture, and supply of Fluoroproducts and technologies. We are committed to developing sustainable solutions to advance life around the world, through responsible management of resources and engagement with all our partners from our local communities, our suppliers, our people, our customers and the future generations to come. Over the last 5 years, Koura has focused on a series of strategic investments to develop environmentally sustainable solutions for the products we make. The most recent example is our focus to develop and produce a secure supply of low global warming potential (GWP) propellant that meets the regulatory and commercial needs of our customers. That effort led the Koura R&D team to successfully develop the Zephex® 152a inhaler innovation. This metered dose inhaler (MDI) propellant reduces the carbon footprint of pMDI by more than 90%, when compared to other MDI propellants. Chiesi Group have been in the vanguard of product adoption and as a result of this partnership we are now in a position to produce this new sustainable, greener, environmentally friendly pressurised metered-dose inhalers (pMDI) for patients with asthma and chronic obstructive pulmonary disease (COPD). The HFA 152a propellant innovation ensures patients can continue to access the treatments they need while protecting the environment in which we all live.”

Our impact across the globe

Beehives Project

France

Beehives Project

At Chiesi France, four beehives were installed on the building’s roof at our manufacturing site. They were regularly visited by a beekeeper who tended to the hives and to the bees.

The annual honey harvest was offered to Chiesi employees. The initiative was accompanied by the organisation of a workshop for increasing awareness around the preservation of bees.

Take Air

United Kingdom

Take Air

In January 2021, Chiesi UK launched the Take AIR (Take Action for Inhaler Recycling) pilot scheme. Within the scheme, the plastic components of inhalers are recycled into the plastic supply chain and any remaining propellant gas is extracted and reused in the refrigeration and air conditioning industry. Non-recyclable materials are converted into energy through energy from- waste by high temperature incineration. A collaboration with the NHS was developed to showcase the value of the scheme in reducing the carbon impact of inhalers and the commitments from Chiesi to help the NHS achieve their Net Zero targets. An implementation toolkit was developed to support the NHS in replicating the scheme and achieving carbon emission savings on an even greater scale. By the end of 2021, 147 pharmacies and 3 hospitals had participated in the scheme and 20,008 inhalers were returned by patients. Overall, 118 tonnes of CO2e could be captured.

Dürrenstein-Lassingtal

Austria

World Natural Heritage Dürrenstein-Lassingtal

In Austria, Chiesi has been supporting  the foundation in charge of protecting  the Dürrenstein-Lassingtal region. The work of the foundation includes teaching people and providing them  with an understanding of the crucial ecological processes required to protect  this wilderness area. This initiative,  which raises awareness internally on biodiversity and local ecology, benefits the environment by preserving a UNESCO certified World Heritage Site.

EcoDrone seed ball shooting

Turkey

EcoDrone seed ball shooting

The objective of the initiative was to partner with the local vendor Ecording to conduct seed ball shooting for the ecoDrone-labeled product through awareness sessions and workshops, ultimately supporting female workers in earning an income. ecoDrone is an unmanned aerial vehicle developed by Ecording which delivers airborne seed ball shots in hard-to-reach areas that need to be reforested. The seed balls are produced by women who live in rural areas who help to sow the products. Ecording provides these women with a training around the unique seed ball materials and how to produce and purchase them. Through this, they create an alternative source of income for women in these areas and enable them to participate in the fight against the climate crisis.

Community

We care for the communities where we operate, creating shared value and deepening our local connections. We are committed to creating an impact, not only on patients, but also on societal health and well-being more widely

The big picture

The 2021 Edelman Trust Barometer Report has revealed that the public places greater trust in businesses in certain countries than their own national governments. Within this context, businesses are viewed as capable of bringing about positive change within the wider community, both in terms of their ethical aptitude and their competence to reach those objectives. By becoming agents of social transformation through collaborations with external partners in their local communities, businesses play an integral role in contributing and doing their part to help achieve global societal and planetary goals. They are also active providers of aid and donations to the communities they operate in.

The Chiesi view

Engaging with and supporting the community is a significant part of our success as a company and promotes long-term sustainable growth which benefits all our stakeholders.

“Contributing to the development of the local communities in which the company operates” is one of the common benefit purposes that Chiesi has written in its bylaws, highlighting the relevance of this topic for the company.

To this end, at corporate level there is a dedicated committee, the Committee for Social and Community Development Activities, devoted to defining the strategy that the Group aims to follow in order to promote the development of the local communities in which Chiesi is based.

Our ambition

At Chiesi, the “shared value” approach is central to the work we carry out as a B Corp. The We ACT programme encompasses Chiesi’s community-based initiatives in which we contribute to and take care of the communities where we operate.  The work we undertake in the wider community includes both financial contributions, goods and drugs donations, and voluntary work carried out by our people. We have a dual approach to our community outreach efforts, which are, on the one hand, based within the work we carry out in the municipality of Parma, where Chiesi headquarters are situated, and on the other hand, extended at global level in the communities across our network of affiliates.

22

Donations and other contributions with social purposes, as identified by the Business for Societal Impact Guidance Manual, such as sponsorships and External Clinical Scientific Test & Studies.

80,000

units of Chiesi drugs donated

€10.3

total value of drugs donated

1,000

employees involved in Group volunteering overall

5,700

hours spent volunteering at Group level

Challenges

In 2021, the global health pandemic placed a tremendous strain on society at large, and posed a number of challenges to many local communities. With this in mind, last year, several of our outreach programmes tackled or addressed some of these concerns.

Spotlight

We ACT Day

WE ACT Day 2021

The term “We Act – We Actively Care Tomorrow” was introduced by Chiesi in

2018 as the name for its awareness-raising programme, with the purpose to involve all its employees in promoting a mindful and alternative way of acting and generating a positive impact on society and the environment. We ACT Day is a global event that engages all Chiesi people worldwide to spread the shared value mindset and implement the principles of the We Act Sustainability Manifesto through specific initiatives and projects. Chiesi typically celebrates the We Act Day in the week of September 25th: this date was chosen as it coincides with the anniversary of the release of the 17 Sustainable Development Goals (SDGs) by the United Nations. Due to the complex situation of the pandemic and with the purpose to involve all Chiesi affiliates around the globe, the 2021 edition of the We Act Day has been a virtual event (celebrated on September 23rd), which was live streamed from Chiesi’s Parma Headquarters to all 30 of the Group’s affiliates. The theme for the 2021 edition of We ACT Day was #EveryStoryCounts and the event was structured around different session, which involved employees as well as institution representatives, experts, the academic world, and associations. The key topics were We ACT for our People, We ACT for our Community, We ACT for our Patients, We ACT to zero Impact, in order to mirror the four cornerstones on which the Group’s strategy and actions are based.

Economic value generated

Through our global operations, at Chiesi we aim to create value for a wide range of stakeholders, including our local communities, capital providers, Public Administration, employees and collaborators, suppliers and vendors. The amount of wealth generated in 2021 and distributed to Chiesi’s many stakeholders is summarised in the table above.

The Economic Value Generated indicates the wealth created based on our operations and amounted to €2.43 billion in 2021. 77.6% of the economic value generated was distributed to stakeholders, and 22.4% was retained by the company.

Driving impact for our communities

A set of broad guidelines are defined at corporate level, to ensure that across the company, activities are being chosen based on the three main areas of intervention: Environment, Health and Education; Community Development; and Emergency. The work carried out in the different affiliates is collected and analysed on a yearly basis, sharing best practices so that we can learn from and improve the way we carry out our local projects.

Partnerships for sustainable care

In addition to the partnerships that take place at local level, Chiesi also participates in several partnerships that take place at national and international level, which are driven from the Parma headquarters. Other long-standing partnerships include Fondazione ASPHI, Italy for Climate, The Regenerative Society Foundation, Fondazione Sodalitas, Fondo Ambiente Italiano (FAI) and Parma, io ci sto!

Concrete change towards a more sustainable and inclusive future

A word from our stakeholders

Elena Detomati

Digital and Education Strategist, InVento Lab

B Corp School links Benefit Corporations with companies that exhibit
its values to schools, in order to discover new talent and diffuse the Benefit values to high school and university students. To date, the project has involved thousands of students throughout Italy and an incredible network of B Corp and institutional partners. This makes B Corp School a project with a great social impact, especially for companies that decide to become not only mentors for children, but also spokespeople for a concrete change towards a more sustainable and inclusive future, both for young people and for the local area in which they operate.

With B Corp School, students are guided through the creation of a real B Startup on the model of B Corp companies. At the end of the journey, all the startups, together with the B Corp that led them, participate in the Changemaker Competition, an opportunity for great national visibility and a chance for young talent to network with a variety of companies. Thanks to this solid collaboration with Chiesi, we have improved our social impact and contributed to SDG #4, involving three high schools, three classes, over 70 students and families and over 1,800 hours of training.”

Our impact across the globe

Million Forest public benefit project

China

Million Forest public benefit project

To plant trees in the desert of Inner Mongolia and visit a B-Corp company in the snowy mountain should be an amazing journey. Some of the employees from Chiesi China took part in such an activity in Autumn 2021. To minimise their footprint on the journey, all participants travelled on public transportation, taking their own cup, tableware, towel and toothbrush. Chiesi China committed to donating one tree per employee, totaling 530 trees in a charity programme called “Million Forest”. Through this programme, 5 million trees have been planted, and a 20km long forest has been formed putting an end to desertification.

“Help Her Read” programme

Pakistan

“Help Her Read” programme to educate women

In Support of Women’s Education, Chiesi Pakistan has partnered with a non-profit organisation to support an adult literacy programme called Help Her Read! run by The Citizens Foundation on “International Literacy Day”. The Aagahi Adult Literacy Programme is a 4 month functional literacy programme which thousands of women across Pakistan benefit from every year. The programme provides women with the chance to further their own education while supporting their children’s education and also helps them gain employment towards building a better quality of life.

‘Smoking prevention youth’

Netherlands

Support the foundation ‘Smoking prevention youth’

In the Netherlands we support the foundation “Smoking Prevention Youth” on a structural basis. This foundation has one goal: to banish tobacco from society and make smoking history. To achieve this, it is of the utmost importance that children do not take up smoking at all. Chiesi Netherlands has decided, after an internal analysis, that supporting this group  in their fight against the tobacco industry and the government, is a meaningful way to join this debate and bring about real change.

Projeto Guri

Brazil

Projeto Guri

We partnered with Projeto Guri, a fundamental part of Guri’s artistic and educational structure which carries out music teaching and social work with girls in the Sao Paulo region. This programme gives the students the chance to improve their artistic skills while also learning about different music languages and techniques, but also about responsibility, respect, cooperation and solidarity. Besides working with repertoires and learning closely with renowned local and foreign musicians, the students interact with different contexts and languages during rehearsals. Through discussions and debate exercises, this diverse setting turns music teaching and practicing into an empowering experience enriched with exchange, thereby enabling a deep reflection about each one’s role in society, as citizens who are aware of their rights and opportunities.

Value chain

In order to allow patients to continue receiving the therapies they need, we constantly seek ways to improve and deepen our links with our partners. These efforts can lead to building a robust and long-lasting relationship with our external suppliers and Contract Manufacturing Organisations (CMOs).

The big picture

The lingering effects of the Covid-19 pandemic on global value chain management prevailed in 2021, as lockdowns and travel restrictions disrupted activity in every industry and every part of the economy. Manufacturing was heavily affected, as raw material flows slowed, or even stopped completely, affecting the value of finished goods. While demand vanished in some sectors, it escalated elsewhere, causing businesses to significantly alter the structure and function of their supply chains, focusing on more flexibility, agility and resilience. This shake-up also prompted the adoption of an approach that would physically change value chain management, increasing the number of collaborations and partnerships embarked upon and reassessing value-chain footprints.

The Chiesi view

Chiesi is committed to develop and strengthen our relationships with our suppliers and other partners throughout the entire value chain. This is important so that we can ensure there are no disruptions in our end-to-end value chain, so that patients will continue to be able to receive the therapies that they need.

Our ambition

Chiesi’s value chain network is a crucial part of our production and distribution process, ensuring that therapies reach those patients that need them. In this regard, our purpose in the area of value chain management is to ensure end-to-end oversight of value and supply, from procuring active ingredients, packaging and raw materials to deliver the final product in each of the countries we supply to directly. In addition to this primary ambition, Chiesi is also committed to ensuring we manage our value chain as responsibly as possible. We do this by promoting our principles with regards to sustainable governance and by ensuring supplier compliance on a number of issues, such as human rights, environmental protection and ethical working methods. By doing so, we can leverage mutual advancement of our business, its people and the planet.

(Click to enlarge)

Challenges

The health pandemic altered the way that we needed to manage our value chains. Despite this, Chiesi’s manufacturing and distribution network remained fully operational.  We are in constant contact with our network of partners, suppliers and distributors involved across the value chain to identify potential risks and take appropriate measures to avoid any disruption. No supply disruptions of Chiesi’s products are currently anticipated. Chiesi will continue to take the necessary steps necessary to safeguard the reliable supply of its medicines as this global situation evolves.

Code of Interdependence

In 2019 Chiesi co-created, alongside its business partners and suppliers, the Code of Interdependence, the code of conduct for suppliers and all strategic partners, which has been rolled out globally.

The format used for the Code of Interdependence changes the concept of a value chain into an ecosystem, which recognises each of us as essential to the others within a process of mutual learning and co-evolution. The Code includes both mandatory requirements, which represents a minimum level to be implemented, and to “improvement actions” which represent a guide for those that wish to go even further towards implementing future improvements of the principles outlined in the document.

In 2021, the Code of Interdependence was revised to include two new SDGs, now reaching a number of 11 SDGs, in total. These new additions include UN SDG #5 Gender Equality, and UN SDG #11 Sustainable Cities and Communities. Despite the challenge of incorporating such a large number of SDGs into the Code, by doing so, we ensure we are always pushing the boundaries further, to deepen our impact while guiding and supporting our suppliers to do the same.

“It’s not just a code of conduct, it’s a set of principles that first and foremost we respect within Chiesi, but that also we ask for the same level of respect from our partners.”

Guido D’AgostinoHead of Global Procurement

Vendor qualification

In order to ensure comprehensive engagement globally, at affiliate level, we have rolled out a qualification process to establish a consistent supplier governance framework. The vendor qualification process, which was revised in 2019 to incorporate sustainability parametres, follows a phased approach and now includes affiliates in 11 markets on top of our Head Quarter spend. In 2021 Spain, China, Poland, Greece, Austria and the USA were included in this process, so that we are now covering about 90% of Chiesi spend with vendor qualification.

(Click to enlarge)

Biotech Centre of Excellence

In December 2021, Chiesi announced the opening of a new Biotech Centre of Excellence, which will be located next to the current Italian production plant of Chiesi in Parma and will be operational as of 2024. This 85 million euro investment project will support new R&D activities for Chiesi’s own internal organic growth but will also present options for Chiesi to become a knowhow provider in the area of Biotechnology. The investment will help consolidate knowhow in biotech products within our pipeline and facilitate the integration of new products. The scope for this new project has the ability to encompass the entire end-to-end value chain with the first products expected to leave the plant by 2025.In line with Chiesi’s commitment as a B Corp, the Centre will be designed in a sustainable way and will conform to LEED criteria.

Partnerships for sustainable care

One of the main areas where we aim to create impact in our value chain is by encouraging our suppliers and partners to reduce their carbon footprint. This will simultaneously help Chiesi in our quest to reach our own environmental targets. Chiesi is conscious that it has wide reaching commitments and expects the same from its suppliers. We realise that for many of our partners, these expectations can be challenging and overwhelming. To aid our suppliers as part of our joint commitment to improve sustainability dimensions, we have been sharing information with our suppliers on sustainability topics, and advising them on possible pathways towards achieving their goals.

Recognising the efforts of our suppliers towards reducing the environmental footprint

A word from our stakeholders

Michele Arduini

Managing Director at IMA Life

IMA S.p.A. started a project with Valle Morosina S.p.A. in 2020, purchasing carbon credits annually, voluntarily, in a number equal to the offsetting of the Group’s direct emissions (from the use of fuels and refrigerants) and indirect (from electricity use), thus including the environmental impact of both Italian andforeign companies. As part of the same project, IMA has obtained certification from a third party on compliance with the ßNeutral standard, which provides for a commitment by IMA to gradually reduce the quantity of emissions generatedby its production process, and to offset / neutralise residual emissions through the purchase of the aforementioned carbon credits.IMA is committed to reducing its emissions for the sites in which it operates through the request for electricity supply certified with a guarantee of origin from renewable sources In order to be able to effectively monitor emissions and evaluate interventions on the work activities that generate emission categories with the highest impact, in 2021 IMA implemented, with third party certification,a greenhouse gas emissions management system for the organisation according to the ISO 14064-1 standard in compliance with UNI/PdR 99: 2021 (referred toin the ßNeutral). This management system is subject to annual inspection and verification by the certifying body. In 2021, the project was awarded the Chiesi Sustainability Project Award.”

Our impact across the globe

Sustainable Pharmacy Awards

Spain

Sustainable Pharmacy Awards

The Sustainable Pharmacy Awards is an initiative which aims to promote and encourage innovation, effort,commitment, and creativity inthe development of sustainable pharmacies. The award, in its first edition, is aimed at all Spanish pharmacies that are aligned with the “10 Chiesi Sustainable Pharmacyrecommendations”. The three awards are worth €6,000 and recognise pharmacies that foster a culture of sustainability in their establishments and promote initiatives at local level. Interested pharmacies can participatec in three different categories: “the best sustainable transformation of the pharmacy”, “the best new project in the pharmacy”, and “the best sustainable showcase”.

Adoption of new Green procurement policy

Hungary

Adoption of new Green procurement policy

In Hungary, we implemented thecompany’s new green procurementpolicy. Initially, we were facing some challenges in finding new office supplies that meet the required standards as “green” products. Once these were identified, however, the procurement process becameeasy to manage. Now we can proudly say that we use ecological cleaning products, recyclable materials, and rechargeable batteries. We have changed our office coffee to an organic fair trade option and have adapted many other changes that make our affiliate office greener. We firmly believe that every change, large and small, is worth the effort and withour actions on green procurement we also hope to set an example for other affiliates.

BravoSolution

Germany

BravoSolution

The topics of sustainability and social responsibility are important cornerstones of our daily activities at Chiesi GmbH. Our partners and suppliers play an important role in this and we would like to encourage them to give these topics the same importance as we do. For this reason, we were pleased to be able to expand our existing supplier qualification process in 2020 with the online solution BravoSolution from JAGGAER. To date, 74 partners have successfully completed our qualification process and have shared information with us on cost effectiveness, existing certifications, social responsibility and ethics & anticorruption. This is an important step for Chiesi towards a responsible and sustainable supply chain.

Code of Interdependence Supplier Commitment

Mexico

Code of Interdependence Supplier Commitment

Chiesi’s Code of Interdependence represents a fundamental part of Chiesi’s evolution towards full sustainability. Chiesi Mexico made known its solemn pledge to the Code of Interdependence and its willingness to involve all partners and suppliers in this journey by sending a communication to all partners. In it, the affiliate underlined its dedication to collaborate with subsidiaries and strategic partners and asked each of its suppliers to work alongside the company by signing a Commitment Letter to confirm their assurance to follow the Code of Interdependence guidelines, to align themselves and to act in accordance with it.

People

Chiesi is committed to serving patients with outstanding therapeutic solutions that improve their quality of life, so that they can live as part of a community, undefined by their disease, while also delivering shared value for wider society and the planet.

The big picture

Around the world, many people have used the pandemic years as an opportunity to re-evaluate and reset their expectations in terms of how they want to make a living. Employees look for a greater sense of purpose from work and alignment with their own personal values. Gartner has identified topics of fairness, equity and inclusion as priorities for attracting and retaining top talent. This includes access to hybrid and remote work; flexibility is an expectation in our post-pandemic world. Finally, as LinkedIn has pointed out, people increasingly want to work for employers who value their physical and emotional wellbeing. Employers therefore need to meet employees where they are – while also providing resources to prevent burnout and ensure work-life balance is maintained.

The Chiesi view

In the past year, society had to reassess the way it navigates life given the changing restrictions due to the global health pandemic. This has had a profound effect on our well-being and in a work setting, it has also changed the way we view the traditional work-life balance. At Chiesi, we have paid special attention to the well-being of our employees during these trying times, introducing a hybrid working model in those regions where Covid-19 health restrictions allowed it.

Our ambition

Our ambition is to prioritise fairness and equality allowing for a workplace where everybody is valued. We nurture cultural perspectives and diverse talents and we inspire a culture of inclusion. By doing so, we believe that we can reach the best business outcomes for all stakeholders.

Our workforce

6,146
Internal Employees
54
Women
46
Men
406
External Collaborators
994
Employees working in R&D
66
Women in R&D

Challenges

During 2021, the Covid-19 crisis persisted, which made us continue to prioritise the care and well-being of our people. We adapted working models so that colleagues were able to work from home, supporting them as they continued to deal with the challenges of these uncertain times. Thanks to our flexible working policy, our IT infrastructure and employee support programmes, we were able to continue working to guarantee the ongoing supply of our therapies to the patients who need them as well as putting systems and procedures in place to safeguard those critical workers that had to physically be on site in our facilities to ensure that the production and distribution of our products continued.

Furthering our Diversity & Inclusion Awareness Programme

To advance on our D&I journey, we continued to roll out our awareness programme throughout different levels of the organisation. The Executive Committee pursued our “From Visible to invisible” educative training programme, which seeks to raise awareness about the different D&I dimensions. This training will continue in 2022 as a global project. Through a collaboration with consultancy Global Diversity Practice we guided all Chiesi leadership teams through a soft learning programme to address unconscious bias and encourage inclusive teams and leadership.

Spotlight

Fairness and Equality

2021 marked the starting point to focus on ensuring all people processes in the business are free from bias. As part of this endeavour, we started a global initiative called the Global Gender Equality Challenge. The aim of this project is to reach equal pay, by closing the gender pay gap, and establishing equal opportunities, balancing the gap between men and women in leadership positions.

In Chiesi Group, the unexplained pay gap is approximately 1.5%, which is lower than the reference benchmark (2% -5%) for organisations starting on their pay equity journey for the first year. Within the pharmaceutical industry, the average unexplained pay gap is 2.2%. Chiesi has set the goal to reduce the unexplained pay gap and reach Equal Pay – no difference in pay by gender for same position and at same conditions – by 2023.

But equality and fairness are not just about the pay: among other things, this approach also involves a huge work on recruitment practices, people development and career opportunities. Considering the headcount in December 2021, at Group level the Chiesi workforce is gender balanced and composed of slightly more females (54%). The greatest difference can be found in leadership positions where males account for about 60% of staff. Compared to 2019, there is an encouraging trend towards gender balance in leadership positions (about +5% in 2021 vs September 2019). Nevertheless, our equality journey is an ongoing process and we continue to seek improvement.

Spotlight

Health, safety and well-being

In 2021, we created the first global Well-being policy at Chiesi. This has been developed in the form of a global guideline and the programmes are selected at local level. We also launched dedicated guidelines which focus on several pillars: Work Life Harmony, Volunteering, Well-being Education, Healthcare, Welfare. We provided individual support on well-being, such as life-coaching and psychological support which we offered through webinars to educate people on topics such as families, relationships with children, education, and time saving initiatives. Going forward, we aim to carry out periodical surveys amongst our colleagues to better understand the well-being levels of our workforce.

In 2021, a total of 19 work-related injuries were reported. No high consequence injuries or fatalities were recorded. There is a decrease in the number of injuries in 2021 compared to 2020, which leads to a general decrease in the overall injury rate.

A word from our stakeholders

Marzia Iori

Life Coach

I have had the pleasure and honour of working at Chiesi since 2017 in People Care projects both at individual level and team level, providing courses on empathy, emotions, through theatre, music and writing. In life coaching people are free to bring any theme (work or otherwise) in an environment of maximum trust and confidentiality. It is a gift from the company to the participant, without any obligations. With team coaching, well-being is aimed at the team so that people can find sustainable and inclusive ways of working together. In recent years, my colleagues and I have witnessed people who have achieved important personal and/or professional goals and people who have rediscovered self-awareness and pleasure in the work they do. In the team setting, members have learned the importance of learning from each other, of nourishing each other in an environment of mutual trust and respect. The company’s openness to welcome and introduce more innovative forms of training, tailored to adult learning, has allowed the provision of webinars and courses on topics such as empathy and emotions. Through tools such as writing, music and theatre, people felt free to express themselves, to reflect and have fun while learning in a relaxed environment in contrast to very difficult historical times. So I would say thank you to Chiesi, and specifically to the people I interact with, for opening up to the “new” and in offering employee tools aimed at a continuous increase in wellbeing.

Our impact across the globe

Work-life balance package for parents

Mexico

Work-life balance package for parents

As a result of the global pandemic, we started offering several work-life

balance benefits for parents, including free psychological support (available also for all other employees) and flexible work schedules for families with children in home-schooling, allowing parents to support their kids in their studies without work conflicts. We also provided a work-life balance course to give our employees the right tools to achieve said balance. Finally, we implemented a Flex Time modality in which our staff can choose the schedule that best suits them and their family dynamics, always complying with the 40 hours per week and fulfilling their own objectives.

Você Feliz Programme

Brazil

Você Feliz Programme

Você + Feliz is the name of our local wellbeing programme, launched in

2021, with the aim to stimulate and create opportunities for our employees to further exercise the pursuit of happiness in everyday life and reach a better balance of physical and mental health. The programme is divided into three pillars: physical health, mental health, and work environment. Examples of actions we carried out included sharing biweekly content relating to wellbeing and other employee stories, access to corporate physical activity platform Gympass, and the provision of workshops relating to time management for all Chiesi Brazil employees.

Psychological support to employees

Germany

Psychological support to employees

We implemented several support offers over the year for our employees to help them get through the global health crisis caused by Covid-19. This included an employee assistance service so that employees could ask for help or support on anything they needed. We also offered the “self-management in times of crisis” programme for all leaders and employees. On the whole, we received very positive feedback regarding our management of the crisis from all employees.

Mental wellbeing of employees

United Kingdom

Mental wellbeing of employees

In order to support employees with a focus on mental wellbeing, given the impact of the pandemic we hosted a number of workshops and campaigns across the year. These included Mental Health First Aiders support workshops, a webinar on Children’s Mental Health for parents or carers working from home, a health and suicide awareness focus on International Men’s Day, the sending of care packages to all employees to block out time to catch up through our Time to talk programme, and Get Fit Feb – an initiative to encourage people to get active while working from home fulltime.

Looking to the future

Maria Paola Chiesi

Head of Shared Value & Sustainability

We have made headway towards our sustainability commitments in 2021, and for that we can be proud. Given the challenges we faced this year, both globally and on our doorstep, this was not an easy achievement. As we manoeuvred

through the ongoing Covid-19 pandemic and its effects on the global economy, we also became stronger to face the road ahead – further advancing towards our sustainability goals and continuing to provide high-quality care for patients.

Looking at the future, I know we will make strides towards our commitments on environmental, societal and inclusive topics, given the great impetus placed on these goals both internally and externally. We will tirelessly advocate these

efforts, as stewards of sustainable business and shared value, showing how these principles are core in the biopharmaceutical sector, to create value for patients and the whole society.

Carbon minimal inhaler clinical trial results

Production of low-carbon propellant devices

B-Corp recertification